Free shipping on all orders over $ 500

LY2334737

Cat. No. M8960
LY2334737 Structure
Size Price Availability
5mg USD 270  USD270 4-7 Days
10mg USD 420  USD420 4-7 Days
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

LY2334737 is an orally available valproic acid ester of gemcitabine, a broad-spectrum antimetabolite with antineoplastic activity. Gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate and triphosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually the induction of apoptosis.

In vivo: Oral treatment of xenograft models with 3.2 mg/kg LY2334737 once a day for 21 days showed greater tumor growth inhibition of CES2 transfectant than the mock transfectant (P ≤ 0.001).

Chemical Information
Molecular Weight 389.39
Formula C17H25F2N3O5
CAS Number 892128-60-8
Form Solid
Solubility (25°C) DMSO 10 mM
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Pratt SE, et al. Clin Cancer Res. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells.

[2] Francia G, et al. Mol Cancer Ther. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.

[3] Koolen SL, et al. Clin Cancer Res. Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.

Related DNA/RNA Synthesis Products
DTP3 TFA

DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor.

Mating Factor α (1-6)

Mating Factor α (1-6) is a mating factor produced by α-mating type cells of Saccharomyces cerevisiae and an acts as an inhibitor of the initiation of DNA synthesis in the cells.

Polynucleotide kinase

Polynucleotide Kinase is a DNA repair enzyme.

Tetrapeptide

Tetrapeptide, an analogue of α-MSH, induces melanin synthesis.

Branaplam hydrochloride

Branaplam hydrochloride is an orally active, brain-permeable, selective modulator of SMN2 splicing, with an EC50 of 20 nM for SMN, and enhances full-length SMN protein and prolongs survival in a mouse model of severe spinal muscular atrophy (SMA). Branaplam hydrochloride also inhibits hERG with an IC50 of 6.3 μM.

  Catalog
Abmole Inhibitor Catalog




Keywords: LY2334737 supplier, DNA/RNA Synthesis, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.